Novogene Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
August 10, 2022 at 05:51 am EDT
Share
Novogene Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 849.13 million compared to CNY 800.32 million a year ago. Revenue was CNY 849.72 million compared to CNY 801.73 million a year ago. Net income was CNY 56.7 million compared to CNY 81.58 million a year ago. Basic earnings per share from continuing operations was CNY 0.14 compared to CNY 0.22 a year ago. Diluted earnings per share from continuing operations was CNY 0.14 compared to CNY 0.22 a year ago.
Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.
NOVOGENE CO., LTD. 
